• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Research Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    4/20/26 5:07:07 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    nrc20260409_8k.htm
    false 0000070487 0000070487 2026-04-15 2026-04-15
     
    --12-31
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________________________________________________
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
    April 15, 2026
    _______________________________________________________________________________
     
    NRC Health
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-35929
    47-0634000
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    1245 Q Street, Lincoln, Nebraska
    68508
    (Address of principal executive offices)
    (Zip Code)
     
    (402) 475-2525
    (Registrant's telephone number, including area code)
     
    National Research Corporation
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
       
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    $.001 Par Value Common Stock NRC The NASDAQ Stock Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
     
    Emerging growth company ☐
     
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
       
     
    The information set forth under Item 5.03 below under the heading “Declassification of the Board of Directors” is incorporated herein by reference.
       
      On April 15, 2026, the Compensation and Talent Committee (the “Committee”) of the Board of Directors of NRC Health approved an amendment to the terms of the equity award made to Shane Harrison on September 29, 2025, which was comprised of 172,000 shares of restricted stock.  The Committee amended the award to permit the voting and receipt of dividends with respect to unvested shares underlying the award.
       
    Item 5.03
    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
       
     
    On April 15, 2026, National Research Corporation (the “Company”) changed its corporate name to NRC Health (the “Name Change”) pursuant to an amendment to the Company’s certificate of incorporation filed with the Delaware Secretary of State and effective on April 15, 2026 (the “Charter Amendment”). Pursuant to Delaware law, a stockholder vote was not necessary to effectuate the Name Change and it does not affect the rights of the Company’s stockholders. The Company has used the brand name NRC Health since 2016. There is no change to the Company’s “NRC” ticker symbol on the NASDAQ Stock Market. A copy of the Charter Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.
     
    Also on April 15, 2026, the Company’s Board of Directors (the “Board”) adopted and approved, effective April 15, 2026, amended and restated Bylaws of the Company (as amended and restated, the “A&R Bylaws”). The A&R Bylaws, among other things, reflect the Name Change. Additional changes made by the A&R Bylaws are described below.
     
    Declassification of the Board of Directors
     
    The A&R Bylaws declassify the Board. Previously, the Board was separated into three classes, with each class of directors serving a three-year term. Following the declassification, all directors will be subject to reelection on an annual basis at the Company’s annual shareholder meeting and will serve an approximately one-year term, or until their successors are duly elected and qualified.
     
    In order to facilitate the implementation of the declassification at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), which is to be held on June 23, 2026, on April 15, 2026 each of the directors who had a term that was to extend beyond the Annual Meeting (which includes Donald Berwick, Trent Green, Michael Hays, Stephen Lockhart, and John Nunnelly) submitted a resignation as director, to be effective immediately prior to the election of directors at the Annual Meeting, resigning from the balance of their term. Directors Parul Bhandari and Penny Wheeler have terms that are already scheduled to expire at the Annual Meeting. All seven incumbent directors have been nominated by the Board for reelection at the Annual Meeting, to serve until the Company’s 2027 annual meeting of stockholders or until their successors are duly elected and qualified. The foregoing resignations are intended solely to facilitate the declassification of the Board and permit a stockholder vote to re-elect all current Board members at the Annual Meeting, and are not a result of any director’s disagreement with the Company or an indication of any director’s desire to cease serving on the Board.
     
    Other Changes
     
    In addition to the declassification of the Board, the A&R Bylaws:
     
    ●       Update certain deadlines, dates, and procedures for establishing an annual or special stockholder meeting and for stockholders to provide notice of the nomination of directors (outside of “proxy access”) and the submission of proposals for consideration at stockholder meetings;
    ●        Provide that the Board shall be comprised of a maximum of 12 directors (previously there was no maximum);
    ●        Specifically provide for the position of Chair of the Board and related authority and responsibilities; and
    ●        Contain certain other conforming, ministerial, administrative, and minor miscellaneous changes.
     
    The foregoing description does not purport to be complete and is qualified in its entirety by reference to the full text of the A&R Bylaws of the Company, which are filed as Exhibit 3.2 to this Current Report on Form 8-K.
     
     

     
     
    Item 9.01
    Financial Statements and Exhibits.
       
     
    (d)
    Exhibits.
         
     
    EXHIBIT
    NUMBER
    EXHIBIT DESCRIPTION
         
     
    3.1
    Certificate of Amendment to Certificate of Incorporation of NRC Health, dated April 15, 2026
     
     
    3.2
    Amended and Restated Bylaws of NRC Health as of April 15, 2026
         
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    NRC HEALTH
     
    (Registrant)
     
         
    Date: April 20, 2026
    By:
    /s/ Shane Harrison
       
    Shane Harrison
       
    Chief Financial Officer
     
     
    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Rau Jason Russell was granted 60,000 shares (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    3/13/26 4:39:55 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Lockhart Stephen H

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/17/26 7:21:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ann & Robert H. Lurie Children's Hospital of Chicago Expands Partnership with NRC Health to Strengthen Consumer Insight and Online Reputation Strategy

    NRC Health today announced that Ann & Robert H. Lurie Children's Hospital of Chicago has further expanded its partnership to include NRC Health's Reputation, alongside its continued use of NRC Health's Market Insights and Patient Experience solutions. A long-standing NRC Health partner, Lurie Children's has consistently demonstrated a deep commitment to understanding and improving the experiences of the patients, families, and communities it serves. Building on that foundation, this expansion brings new visibility into how the organization is represented across digital channels and how consumer perception drives essential outcomes such as access, trust, and choice. Leaders recognized th

    4/7/26 9:01:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth

    Piedmont, a Georgia-based healthcare system with nationally-ranked clinical programs, has named NRC Health, the leader in healthcare experience management, as its new strategic experience partner to support the organization's mission-driven growth and commitment to making a positive difference in every life it touches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319999984/en/Piedmont, a Georgia-based healthcare system with nationally-ranked clinical programs, has named NRC Health, the leader in healthcare experience management, as its new strategic experience partner to support the organization's mission-driven growth and

    3/19/26 8:01:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Board Authorization of $60 Million Share Repurchase Program

    National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that its Board of Directors authorized a stock repurchase program of up to $60 million of the company's outstanding common stock through March 31, 2028. NRC Health may repurchase shares from time to time in the open market, through privately negotiated transactions and/or other means in compliance with the Securities Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rul

    3/9/26 4:30:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    National Research Corporation filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - NRC HEALTH (0000070487) (Filer)

    4/20/26 5:07:07 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by National Research Corporation

    SCHEDULE 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/27/26 4:35:08 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 filed by National Research Corporation

    S-8 - NATIONAL RESEARCH CORP (0000070487) (Filer)

    3/5/26 12:47:06 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Announces Board Authorization of $60 Million Share Repurchase Program

    National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that its Board of Directors authorized a stock repurchase program of up to $60 million of the company's outstanding common stock through March 31, 2028. NRC Health may repurchase shares from time to time in the open market, through privately negotiated transactions and/or other means in compliance with the Securities Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rul

    3/9/26 4:30:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Provides Business Update

    TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health. TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company's periodic reports filed with the Securities and Exchange Commission. "This TRCV milestone reflects the confidence o

    3/4/26 4:15:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care